Immunoproliferative Disorders

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry


Multiple myeloma (MM) is a B-cell neoplastic disease characterized by excessive number of abnormal plasma cells in the bone marrow and overproduction of intact monoclonal immunoglobulins or light chain (Bence Jones) proteins. The average age of onset is about 60 years and occurs more frequently in men than women. MM is preceded by a premalignant condition termed monoclonal gammopathy of undetermined significance (MGUS). Age is an important prognostic factor, and with each decade from the age of 50 years to over the age of 80, the overall survival declines. This review will provide an update on the clinical management of multiple myeloma.


Multiple myeloma Monoclonal gammopathy of undetermined significance (MGUS) Bence Jones proteins B-cell neoplastic disease 


  1. 1.
    Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Haemat Oncol Clin North Am. 1992;6:225–47.Google Scholar
  2. 2.
    Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50:29–40.PubMedGoogle Scholar
  3. 3.
    Jagannath S. Pathophysiological underpinnings of multiple myeloma progression. J Managed Care Pharm Supplement. 2008;14(7):S7–S11.CrossRefGoogle Scholar
  4. 4.
    Katzel JA, Hari P, Vesole DH. Multiple myeloma: charging toward a bright future. CA Cancer J Clin. 2007;57:301–18.CrossRefPubMedGoogle Scholar
  5. 5.
    Dimopoulos MA, Kastritis E, Rosinol L, Blake J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma bone disease. Haematol Oncol Clin North Am. 2007;21:1035-1-9.Google Scholar
  6. 6.
    Anderson KC,Carrasco RD. Pathogenesis of myeloma. Annual Rev Pathol Mech Dis. 2011;6:24.CrossRefGoogle Scholar
  7. 7.
    Kyle RA. “Benign” monoclonal gammopathy-after 20–35 years of follow up. Mayo Clin Proc. 1993;68:26–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Firkin F. Screening for multiple myeloma. Aust Prescriber. 2009;32:92–94.CrossRefGoogle Scholar
  9. 9.
    Ludwig H, Bolejack V, Crowley J, Blade J, San Miguel J, Kyle RA. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol. 2008;28:1599–160.CrossRefGoogle Scholar
  10. 10.
    Alexanian RA, Balcerzak S, Bonnet JD, Gehan E, Haut A, Hewlett JS, et al. Prognostic factors in multiple myeloma.Cancer.1975;36:1192–201.CrossRefPubMedGoogle Scholar
  11. 11.
    Durrie BGM, Salmon SE, Moon TF. Pretreatment tumour mass, cell kinetics and prognosis in multiple myeloma. Blood. 1980;55:364–72.Google Scholar
  12. 12.
    Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;13 Suppl. 2:56–63.PubMedGoogle Scholar
  13. 13.
    Bataille R, Boccadoro M, Klein B, Durie B, Pileri A. C-Reactive protein and beta-2 microglobulin produce a simple powerful myeloma staging system. Blood 1992;80(3):733–7.PubMedGoogle Scholar
  14. 14.
    Pelliniemi TT, Irjala K, Mattila K, PalkkiK, Rajamaki A, Tienhaara A, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukaemia Group. Blood. 1995;85(3):765–71.PubMedGoogle Scholar
  15. 15.
    Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842–854.CrossRefPubMedGoogle Scholar
  16. 16.
    Greipp PR, Miguel JS, Durie BGM, Crawley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.CrossRefPubMedGoogle Scholar
  17. 17.
    Cassuto JP, Krebs BJ, Vit G. Beta-2 microglobulin a tumour marker of lymphoproliferative disorders. Lancet. 1978;2:108–109.CrossRefPubMedGoogle Scholar
  18. 18.
    Bataille R, Durrie BGM,Grenier J. Serum beta 2 microglobulin and similar markers in multiple myeloma : a reliable marker for staging. Br J Haematol. 1093;55:439–44.Google Scholar
  19. 19.
    Norfolk D,Child JA, Cooper EH, Kerruish S,Ward AM. Serum beta-2 microglobulin in myelomatosis. Potential value in stratification and monitoring. Br J Cancer. 1980;42(4):510–515.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Attal M, Haroussaue JL, Stoppa A M, Sotto JJ, Fuzibet JG, Rosal JF, et al. A prospective randomized trial of autologous bone marrow transplantation for multiple myeloma. Intergroupe Francais du Myeloma. N Engl J Med. 1996;335:91–97.Google Scholar
  21. 21.
    Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet J-O, et al. Intergroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2004; 350:1655–1664.CrossRefGoogle Scholar
  22. 22.
    Hoarousseau J-L. Multiple myeloma in the elderly: When to treat. Whe to go to transplant. 2010. –when -treat.
  23. 23.
    Osborn M, Horvath N, To LB. New drugs for multiple myeloma. Aust Prescriber. 2009;32:95–98.CrossRefGoogle Scholar
  24. 24.
    Joshua DE. Multiple myeloma: the present and the future. AJA. 2005;183:34418.Google Scholar
  25. 25.
    Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benbonbker L, et al. Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myeloma. Haematologica. 2005;90 Suppl 1:17.Google Scholar
  26. 26.
    Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004:350:1655–1664.CrossRefPubMedGoogle Scholar
  27. 27.
    Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley N, et al. Zoledronic acid reduces skeletal –related events in patients with osteolytic metastases. Cancer. 2001;91:1191–1200.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations